Aegis Maintains BioLineRx (BLRX) at Buy; Says Portfolio Continues to Be Undervalued
Tweet Send to a Friend
Aegis Capital maintained its Buy rating and $7 price target on BioLineRx (Nasdaq: BLRX) following news that its BL-8040 for ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
